Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

DecImmune Therapeutics
47 Thorndike St, Suite B11
Cambridge, MA 2141
Phone: 617-278-6655
www.decimmune.com

DecImmune is developing an antibody-based therapeutic that can prevent tissue damage and preserve organ function by inhibiting activation of the N2 neoepitope in the innate autoimmune pathway.

Key Contact
Name
Christopher Mirabelli
Title
CEO
Funding Events

Date
Amount
Type
Investors
Valuation
02/26/13 $2,250,000 Astellas Venture Management
Broadview Ventures
Healthcare Ventures
undisclosed